Are you an entrepreneur who has created an innovative company (less than 5 years old or to be created)? 

Apply to the presentation sessions to:

  • Promote your innovations
  • Receive a speed-monitoring from pharma, biotech, TTO and investors
  • Find partners who could support your project
applyyy

1. Apply before 30th June
Dedicated to entrepreneurs who have created an innovative company (less than 5 years old or to be created)

be selected

2. Be selected
A jury of experts will select the most innovative projects

picto19 (2)

3. Exhibit
The selected candidates will benefit from a space at BioFIT to hold their one-to-one meetings

pitch

4. Pitch
A 6-7 minute presentation of each selected project to potential partners and investors during BioFIT

speed mentoring

5. Receive a speed-mentoring
A jury composed of pharma and investors will give feedback and advice to the presenters

diploma

6. Be awarded
The most innovative start-up will be awarded by the jury of experts of BioFIT

5 Dec 2018  9:00 – 10:30 am

When addressing the contractual relationships between a university and its spin-off: What are the issues regarding equity, royalties and research income? How do VCs, academic institutions, spin-off management and human resources management of the university interact? What are the main conflicts of interests that can arise from people holding dual positions, in the university and in the start-up?

They will share their experiences:

  • Adrian Ibrahim, Head of technology Transfer, Wellcome Sanger Institute (UK)
  • Caroline Barelle, CEO, Elasmogen (UK)
  • Alain Chevallier, Life Sciences Partner, Truffle Capital (FR)
  • Steven J. Klein, Vice President, Business Development IRICoR – Institute for Research in Immunology and Cancer – Commercialization of Research (CA)

Many thanks to MSD for joining BioFIT 2018 as a Bronze Sponsor!

To make a difference in the lives of people globally through innovative medicines, vaccines, and animal health products. MSD is committed to being the premier, research-intensive biopharmaceutical company and is dedicated to providing leading innovations and solutions for today and the future.

Join this key BioFIT 2018 sponsor to have the opportunity to:

  • Identify your organisation with the main partnering event in Europe dedicated to tech transfer, academia-industry collaborations, early-stage innovations and seed investment in Life Sciences
  • Highlight your interest in early-stage innovation
  • Present your ideas and technologies to key innovation players in Life Sciences
  • Enhance your visibility on an international scale and be recognised as a key innovative actor
  • Show your expertise thanks to specific communication tools

 

They were the BioFIT 2017 sponsors: Sanofi, Pfizer, Bayer, Genfit, Lilly, MSD, Merck, Boehringer Ingelheim, Johnson & Johnson Innovation, Novo Nordisk, LFB, PPRS and Trianni.

For more information about the sponsorship opportunities, visit the dedicated site page.

The BioFIT Steering Committee is glad to announce the BioFIT 2018 preliminary conference programme:

PLENARY SESSION: Seed funds crossing borders: How far and how fast is the early-stage investment market in Biotech globalising?

Globalisation of seed investment can be seen as traditionally geographically anchored, now early-stage investors tend to invest in more diversified areas. Where does the money come from? How far is this evolution towards more global funds going? How fast is it going in the investment community? Will it make the investors more risk taking, will it change the risk landscape? Isn’t there today an ill-balance between the geographical origin of the investment capacities and the areas where projects needing equity investment are teeming?

TRACK 1: Best practices in academia-industry R&D collaborations

  • Artificial Intelligence to speed-up drug discovery: The revolutionary road to advance innovation.
  • A prospective overview of the forthcoming cross-sectorial collaborations and licensing deals between human and animal health
  • Beyond shared means, common strategies to collectively succeed
  • Patient organisations to join the pharma-biotech-academia trio: Is a fourth musketeer calling for a new way to manage alliances?

TRACK 2: Nurturing and licensing early-stage assets

  • What is the right balance between equity, royalties, collaborative research income for the academic institutions in the process of spinning out companies?
  • An overview of the recent joint initiatives to derisk academic-origin assets
  • Questioning TTOs financing models: Could their expected financial outcome bias the tech transfer process?
  • Under pressure: How does the urge to bring rare disease therapies create a new range of business models or collaborative models?

TRACK 3: Early-stage innovation: Identify the right funding sources

  • Are philanthropic and alternative sources of soft funding always a free lunch?
  • Shaping your start-up for an industrial exit or an IPO: Are there choices to be made at the very initial stage?
  • Are immunotherapies a new investment Eldorado?
  • Agnostic or pure players in the biotech sector: Who is getting prominent in the early-stage financing rounds?

4 Dec 2018  4:00 – 6:00 pm

Decisions taken at the very initial stage have major consequences for the future development of start-ups with major pitfalls to be avoided. Is it crucial to picture the exit strategy as soon as the company is created? The session relies on its panellists’ stories to go over different approaches of IPO and exits for start-ups.

They will share their experiences:

  • Lucie Ellis, Senior Editor, Pharma Intelligence | Informa (UK) – Moderator
  • Peter Leonardi, CEO, OmniCyte (US)
  • George Hoffman, Co-founder and CEO, Network Immunology (US)
  • Rodolphe Besserve, Head SuFT Advisory, Start-upd & French Techs, Société Générale Corporate Investments and and Banking (FR)

Apply for the presentation sessions! 

> Promote your innovations

> Receive a speed-monitoring from pharma, biotech, TTO and investors

> Find partners who could support your project

 

Are you an entrepreneur who has created an innovative company (less than 5 years old or to be created)?

Apply for the Start-up Slams!

  1. Apply before 30th June: Dedicated to entrepreneurs who have created an innovative company (less than 5 years old or to be created)
  2. Be selected: A jury of experts will select the most innovative projects
  3. Exhibit: The selected candidates will benefit from a space at BioFIT to hold their one-to-one meetings
  4. Pitch: A 6-7 minute presentation of each selected project to potential partners and investors during bioFIT
  5. Receive a speed-mentoring: A jury composed of pharma and investors will give feeback and advice to the presenters
  6. Be awarded: The most innovative start-up will be awarded by the jury of experts of BioFIT

Are you a tech transfer officer with a ready-to-be-licensed technology?

Apply for the Licensing Opportunity Presentations!

  1. Apply: Dedicated to TTO, universities or related structures that have ready-to-be-licensed technologies
  2. Be selected: A jury of experts will select the most innovative technologies
  3. Exhibit: The selected candidates will benefit from a poster’s exhibition at BioFIT describing their out-licensing opportunities
  4. Pitch: Presentations of the selected projects to potential industrial partners during BioFIT
  5. Find partners: The presenters can easily find industrial partners who could in-license their assets

They will speak at BioFIT 2018:

  • Jan Adams, Managing Director, EMBL Ventures (DE)
  • Anjan Aralihalli, Venture Partner, CTI Life Sciences Fund II (CA)
  • Caroline Barelle, CEO, Elasmogen (UK)
  • Yann Barrault, Head of Business Development & Licensing, SATT Grand Centre (FR)
  • Jean-Charles Brosse, Partner Healthcare & Life Sciences, Positive Capital (FR)
  • Alain Chevallier, Life Sciences Partner, Truffle Capital (FR)
  • Lucie Ellis, Senior Editor, Pharma Intelligence | Informa (UK)
  • Juan Garcia, CEO, BioSeed Capital (ES)
  • George Hoffman, Co-founder and CEO, Network Immunology (US)
  • Adrian Ibrahim, Head of Technology Transfer, Wellcome Sanger Institute (UK)
  • Steven J. Klein, Vice President, Business Development, IRICoR – Institute for Research in Immunology and Cancer-Commercialization of Research (CA)
  • Peter Leonardi, CEO, OmniCyte (US)
  • Michael Motz, CBO, NETRIS Pharma (FR)
  • Michael L. Salgaller, Supervisor, Invention Development and Marketing Unit, National Institutes of Health (NIH) | National Cancer Institute (NCI) | Technology Transfer Center (US)
  • Bernd Stowasser, Head of Alliance Management Germany & Global Public Private Partnerships, Sanofi (DE)
  • Jonathan Tobin, Investment Director, Arix Bioscience (UK)
  • Ewa Truchanowicz, Life Sciences Lead, University of Birmingham Enterprise (UK)
  • Bram Vanparys, Investment Director, MS Ventures (NL)

The BioFIT 2018 brochure is now available!

The #BioFIT2018 brochure is now available.

In this document, you will find all the information you need about the 7th edition of the leading partnering event in Europe for technology transfer, academia-industry collaborations and early-stage innovations in the field of Life Sciences.

Many thanks to Boehringer Ingelheim for joining BioFIT 2018 as a Bronze Sponsor!

Innovative medicines for people and animals have for more than 130 years been what the research-driven pharmaceutical company Boehringer Ingelheim stands for. Boehringer Ingelheim  is one of the pharmaceutical industry’s top 20 companies and to this day remains family-owned. Day by day, some 50,000 employees create value through innovation for the three business areas human pharmaceuticals, animal health and biopharmaceutical contract manufacturing.

Join this key BioFIT 2018 sponsor to have the opportunity to:

  • Identify your organisation with the main partnering event in Europe dedicated to tech transfer, academia-industry collaborations, early-stage innovations and seed investment in Life Sciences
  • Highlight your interest in early-stage innovation
  • Present your ideas and technologies to key innovation players in Life Sciences
  • Enhance your visibility on an international scale and be recognised as a key innovative actor
  • Show your expertise thanks to specific communication tools

For more information about the sponsorship opportunities, visit the dedicated site page.